0.75%
11.36%
-1.23%
-10.27%
-45.45%
-54.58%
-42.98%
AI Spotlight on OSUR
Company Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.It operates in two segments, Diagnostics and Molecular Solutions.The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test.
It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services.In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing.Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.OraSure Technologies, Inc.was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Market Data
| Last Price | 4.02 |
| Change Percentage | 0.75% |
| Open | 3.98 |
| Previous Close | 3.99 |
| Market Cap ( Millions) | 300 |
| Volume | 748730 |
| Year High | 8.04 |
| Year Low | 3.52 |
| M A 50 | 3.81 |
| M A 200 | 4.32 |
Financial Ratios
| FCF Yield | 21.37% |
| Dividend Yield | 0.00% |
| ROE | 2.66% |
| Debt / Equity | 2.61% |
| Net Debt / EBIDTA | -1753.17% |
| Price To Book | 0.7 |
| Price Earnings Ratio | 26.34 |
| Price To FCF | 4.68 |
| Price To sales | 1.62 |
| EV / EBITDA | 2.1 |
News
- Jan -27 - OraSure (OSUR) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Jan -27 - New Strong Buy Stocks for January 27th
- Jan -16 - New Strong Buy Stocks for January 16th
- Jan -07 - OraSure to Present at the J.P Morgan Healthcare Conference
- Jan -07 - CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents
- Jan -07 - OraQuick® HIV Self-Test Now Approved for Use in Adolescents
- Dec -26 - OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
- Dec -19 - OraSure Technologies Acquires Sherlock Biosciences
- Dec -11 - OraSure Technologies: Discounted Assets With An Attractive Free Call Option
- Dec -02 - OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
- Nov -18 - OraSure to Participate in Upcoming Investor Conference
- Nov -07 - OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
- Nov -07 - OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
- Nov -06 - OraSure Reports Q3 '24 Revenue of $39.9 Million
- Nov -04 - OraSure: An NCAV Diamond In The COVID Rough
- Oct -22 - OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th
- Oct -04 - Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc
- Sep -09 - OraSure Technologies Elects Jack Kenny to the Board of Directors
- Aug -07 - OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript
- Aug -06 - OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> COVID-19
Expected Growth : 10.98 %
What the company do ?
The COVID-19 rapid antigen self-test from OraSure Technologies, Inc. is a 10-minute, at-home test detecting active COVID-19 infections.
Why we expect these perspectives ?
OraSure Technologies, Inc.'s 10.98% growth is driven by increased demand for COVID-19 testing solutions, government contracts, and emergency use authorizations. The company's molecular diagnostic tests and oral fluid collection devices have become essential tools in the fight against the pandemic, leading to significant revenue growth.
Segment n°2 -> Human Immunodeficiency Virus
Expected Growth : 10.43 %
What the company do ?
HIV is a virus that attacks the body's immune system, making it harder to fight off infections and diseases, as explained by OraSure Technologies, Inc.
Why we expect these perspectives ?
OraSure Technologies, Inc.'s 10.43% growth in Human Immunodeficiency Virus (HIV) segment is driven by increasing adoption of rapid point-of-care diagnostic tests, rising HIV awareness and testing rates, and growing demand for self-testing solutions. Additionally, expansion into new markets, strategic partnerships, and innovative product developments contribute to the segment's growth.
Segment n°3 -> Molecular Sample Management Solutions
Expected Growth : 10.55 %
What the company do ?
Molecular Sample Management Solutions from OraSure Technologies, Inc. provide secure, reliable, and efficient management of biological samples for research, diagnostics, and biobanking applications.
Why we expect these perspectives ?
OraSure Technologies' Molecular Sample Management Solutions growth is driven by increasing demand for COVID-19 testing, adoption of molecular diagnostics in healthcare, and growing need for efficient sample management in research and clinical trials. Additionally, the company's innovative products and strategic partnerships contribute to its 10.55% growth.
Segment n°4 -> Hepatitis C Virus
Expected Growth : 9.95 %
What the company do ?
Hepatitis C Virus (HCV) is a blood-borne viral infection that affects the liver, causing inflammation and potentially leading to liver disease, cirrhosis, or cancer.
Why we expect these perspectives ?
OraSure Technologies' Hepatitis C Virus segment growth of 9.95% is driven by increasing adoption of its point-of-care diagnostic tests, expanding global reach, and rising awareness about Hepatitis C screening. Additionally, growing demand for non-invasive testing and increasing government initiatives for disease prevention and control contribute to the segment's growth.
Segment n°5 -> Risk Assessment Testing
Expected Growth : 10.38 %
What the company do ?
Risk Assessment Testing from OraSure Technologies, Inc. is a rapid point-of-care test that detects HIV and HCV antibodies in 20 minutes.
Why we expect these perspectives ?
OraSure Technologies' 10.38% growth in Risk Assessment Testing is driven by increasing demand for rapid diagnostic tests, expansion into new markets, and strategic partnerships. The company's innovative products, such as the InteliSwab COVID-19 rapid test, have gained traction amidst the pandemic. Additionally, growing awareness of infectious diseases and government initiatives to enhance public health infrastructure have contributed to the segment's growth.
Segment n°6 -> Molecular Services
Expected Growth : 9.95 %
What the company do ?
Molecular Services from OraSure Technologies, Inc. provides molecular diagnostic testing solutions for infectious diseases, including COVID-19, HIV, and HCV.
Why we expect these perspectives ?
OraSure Technologies' Molecular Services segment growth is driven by increasing demand for COVID-19 testing, expansion into new markets, and strategic partnerships. The company's molecular diagnostic products, such as the Omnisample saliva collection device, have seen significant adoption. Additionally, the company's investments in digital health and telehealth platforms have enhanced its offerings, contributing to the 9.95% growth.
Segment n°7 -> Non-product and Services
Expected Growth : 10.43 %
What the company do ?
Non-product and Services from OraSure Technologies, Inc. refers to the company's non-diagnostic and non-testing related offerings, including consulting services and contract manufacturing.
Why we expect these perspectives ?
OraSure Technologies' Non-product and Services segment growth of 10.43% is driven by increasing demand for molecular diagnostic testing, expansion of COVID-19 testing, and growing government and institutional contracts. Additionally, strategic partnerships and collaborations have contributed to the segment's growth, as well as investments in digital health and telehealth platforms.
Segment n°8 -> Other Product and Services
Expected Growth : 9.98 %
What the company do ?
OraSure Technologies, Inc. offers other products and services including oral fluid collection devices, microbiome sampling products, and molecular diagnostic products for various industries.
Why we expect these perspectives ?
OraSure Technologies' Other Product and Services segment growth of 9.98% is driven by increasing demand for molecular diagnostic products, expansion into new markets, and strategic partnerships. Additionally, the company's focus on developing innovative products, such as its oral fluid collection devices, has contributed to the segment's growth.
Orasure Technologies, Inc. Products
| Product Range | What is it ? |
|---|---|
| Oral Fluid Collection Devices | Devices used to collect and stabilize oral fluid samples for diagnostic testing |
| Rapid Point-of-Care Tests | Rapid diagnostic tests that provide quick results for various diseases and conditions |
| Molecular Diagnostic Tests | Tests that use molecular biology techniques to detect and quantify specific genetic material |
| Microbial Detection Tests | Tests that detect and identify microorganisms such as bacteria, viruses, and fungi |
| IntelliSwab | A rapid, oral fluid-based HIV test that provides results in 20 minutes |
| OraQuick | A rapid, oral fluid-based HIV test that provides results in 20 minutes |
| Drugs of Abuse Tests | Tests that detect the presence of drugs and their metabolites in oral fluid, urine, or blood |
OraSure Technologies, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for OraSure Technologies, Inc. is medium due to the presence of alternative diagnostic tests and products in the market.
Bargaining Power Of Customers
The bargaining power of customers for OraSure Technologies, Inc. is low due to the company's strong brand reputation and limited switching costs.
Bargaining Power Of Suppliers
The bargaining power of suppliers for OraSure Technologies, Inc. is medium due to the presence of multiple suppliers and the company's moderate dependence on them.
Threat Of New Entrants
The threat of new entrants for OraSure Technologies, Inc. is low due to the high barriers to entry in the diagnostic testing industry, including regulatory hurdles and high research and development costs.
Intensity Of Rivalry
The intensity of rivalry for OraSure Technologies, Inc. is high due to the presence of several established competitors in the diagnostic testing industry, leading to intense competition for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.04% |
| Debt Cost | 3.95% |
| Equity Weight | 96.96% |
| Equity Cost | 5.09% |
| WACC | 5.05% |
| Leverage | 3.14% |
OraSure Technologies, Inc. : Quality Control
OraSure Technologies, Inc. passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| NEPH | Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and … |
| PDEX | Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that … |
| WRBY | Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and … |
| LMAT | LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing … |
| UTMD | Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
LeMaitre Vascular
A-Score
1-Year Total Return ->
🥈
Utah Medical Products
A-Score
1-Year Total Return ->
🥉
Pro-Dex
A-Score
1-Year Total Return ->
4
Warby Parker
A-Score
1-Year Total Return ->
5
OraSure Technologies
A-Score
1-Year Total Return ->
6
